BioPharmSignal logoBioPharmSignal

Biotech News

Equillium to Participate in the 2026 Jefferies Global Healthcare Conference

Equillium, Inc. (EQ)Equillium, Inc.Conference / presentation

Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55pm EDT.

Members of the Equillium management team will be available to meet with investors who are registered to attend the conference.

About Equillium Equillium is a biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders.

For more information, visit www.equilliumbio.com .

Investor Contact PJ Kelleher LifeSci Advisors, LLC +1-617-430-7579 [email protected]

Related news

ACRSAclaris Therapeutics2026-05-28 12:30 EST

Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

KYMRKymera2026-05-27 11:00 EST

Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

BMYBMYBristol-Myers Squibb Company2026-05-27 10:59 EST

Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

TLSATiziana Life Sciences2026-05-28 11:00 EST

Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York

ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

XFORX4 Pharmaceuticals2026-05-27 11:00 EST

X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

CUECue Biopharma Inc2026-05-21 20:05 EST

Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference

AVTXAvalo Therapeutics2026-07-22 11:00 EST

Avalo Therapeutics to Participate in the BTIG Biotechnology Conference

XGNExagen2026-07-28 13:00 EST

Exagen Inc. to Participate in Upcoming Investor Conference

EQEquillium, Inc.2026-05-20 20:05 EST

Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis

View all latest news

Equillium, Inc.

Immunobiology Company Equillium develops therapies for severe autoimmune and inflammatory disorders using mechanisms intended to restore immune balance. EQ504 EQ504 is a selective aryl hydrocarbon receptor modulator with a multimodal, non-immunosuppressive mechanism designed to support barrier function and regulate tissue...

Recent company news

EQEquillium, Inc.2026-06-02 20:05 EST

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EQEquillium, Inc.2026-05-28 20:05 EST

Equillium to Participate in the 2026 Jefferies Global Healthcare Conference

EQEquillium, Inc.2026-05-20 20:05 EST

Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis

EQEquillium, Inc.2026-05-13 20:01 EST

Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights

EQEquillium, Inc.2026-05-01 20:42 EST

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
2.12 USD
Market cap
176.4M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States